What insurance policy changes affect code C88.4?

There are 4 tracked policy changes affecting code C88.4, including updates from UnitedHealthcare, Blue Cross Blue Shield of North Dakota, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C88.4?

Payers that have issued tracked updates for code C88.4 include: UnitedHealthcare, Blue Cross Blue Shield of North Dakota, Aetna.

How do I get notified when code C88.4 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C88.4. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C88.4?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

C88.4 Insurance Policy Changes

code C88.4 is referenced in 4 tracked payer policy changes from UnitedHealthcare, Blue Cross Blue Shield of North Dakota, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C88.4 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

UnitedHealthcare · Effective Nov 1, 2026Medium impact
Vitamin D Testing
UnitedHealthcare's Medicare Advantage Vitamin D Testing medical policy, in the November 2026 bulletin effective 2026-11-01, removed ICD-10 diagnosis codes C88.4, Z79.60, Z79.61, Z79.620 through Z79.624, Z79.630 through Z79.634, Z79.64, and Z79.69 from the applicable codes list, and updated the CMS related documents list and clinical evidence references. Billing teams should stop relying on the removed diagnosis codes when submitting Vitamin D testing claims for Medicare Advantage members and confirm that remaining claims carry a supported diagnosis.
Blue Cross Blue Shield of North Dakota · Effective Feb 10, 2026Medium impact
Pharmacy Policy Updates
Commercial prior authorization medical drug policies have revisions effective Feb. 10, 2026, including new indications such as Epkinly in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma, Gazyva for active lupus nephritis, Darzalex SQ for high-risk smoldering multiple myeloma, and Bevacizumab for respiratory papillomatosis. Commercial post service claim edit policies for Botox, Dysport, Daxxify, Myobloc, Xeomin, Asparlas, and Besponsa have revisions effective Jan. 1, 2026, with multiple sclerosis coverage moving from G35 to G35.A through G35.D. Vyepti now covers chronic migraine with ICD-10 codes G43.E01, G43.E09, G43.E11, and G43.E19, and the Infugem policy is being retired because the manufacturer discontinued the product.
Blue Cross Blue Shield of North Dakota · Effective Jan 13, 2026Medium impact
Pharmacy Policies Updates
BCBSND's Commercial post service claim edit medical drug policies have revisions effective Dec. 1, 2025, and its Commercial prior authorization medical drug policies have revisions effective Jan. 13, 2026. Most of these policies now separate Length of Authorization durations for initial and renewal periods, add the Appendix A Non-Quantitative Treatment Limitations (NQTL) Factor Checklist, and replace 'coverage' with 'prior authorization validity' in the initial and renewal criteria. Several policies also remove discontinued HCPCS codes, add ICD-10 covered diagnosis codes, and update oncology criteria to align with NCCN guidelines.
Aetna · Identified Aug 13, 2026Medium impact
Paclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)
Aetna considers albumin-bound paclitaxel (Abraxane or generic albumin-bound paclitaxel) medically necessary for the cancers listed in its initial approval criteria, including Kaposi sarcoma, breast cancer, cutaneous melanoma, endometrial carcinoma, ovarian, fallopian tube and primary peritoneal cancer, biliary tract cancers, non-small cell lung cancer, pancreatic adenocarcinoma, small bowel adenocarcinoma, uveal melanoma, ampullary adenocarcinoma, cervical cancer, bladder cancer and vaginal cancer, when each cancer's stated criteria are met. All other indications are considered experimental, investigational, or unproven, including small cell lung cancer, prostate cancer, soft-tissue sarcoma and gastric cancer. Continuation of therapy is medically necessary for an approved indication when there is no evidence of unacceptable toxicity or disease progression on the current regimen.

Watch C88.4

Get one email when a payer policy names C88.4, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Vitamin D Testing

Pharmacy Policy Updates

Pharmacy Policies Updates

Paclitaxel, Albumin-Bound (CPB 0834, reviewed 2026-05-28)

What insurance policy changes affect code C88.4?

Which payers have updated policy for code C88.4?

How do I get notified when code C88.4 policy changes?

Why do payers change policies for code C88.4?